The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Help-4-Hep Launches Free App for People Managing HCV

Back to News Homepage

Next

Repurposing Allergy Meds to Treat Hep C

New, Simplified Treatment for ALL Hepatitis C Genotypes

Print this page

A potential new treatment for Hepatitis C that will shorten treatment time and work on all genotypes is expected in 2018.
New, Simplified Treatment for ALL Hepatitis C Genotypes

Two Companies Enter into Hepatitis C Drug Development Deal

By Catherine Kolonko

Achillion Pharmaceuticals has joined forces with Janssen Pharmaceuticals to develop a short-duration oral regimen to treat chronic hepatitis C, the companies announced.

Both companies have entered into an exclusive worldwide license and collaboration arrangement to develop and commercialize one or more of Achillion’s lead hepatitis C treatments (currently named ACH-3102, ACH-3422) and sovaprevir, according to a release from Janssen, which is owned by Johnson & Johnson. The aim of the partnership will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of the hepatitis C virus, states a Janssen release.

Continue reading this entire article:
http://www.hcplive.com/medical-news/Two-Companies-Enter-into-Hepatitis-C-Drug-Development-Deal

18 Comments
Share
Share

Previous

Help-4-Hep Launches Free App for People Managing HCV

Back to News Homepage

Next

Repurposing Allergy Meds to Treat Hep C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.